Details of Drug-Drug Interaction
| Drug General Information (ID: DDIKMX21ZT) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Abacavir | Drug Info | Orlistat | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Anti-Hiv Agents | Antiobesity Agents | |||||||
| Structure | |||||||||
| Mechanism of Abacavir-Orlistat Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Altered absorption (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Abacavir | Orlistat | |||||||
| Mechanism | Absorption possibly altered by orlistat | Orlistat | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacokinetic | ||||||||
| Factor Description | Alters the absorption of the drug, leading to changes in the plasma concentration of the drug and affecting the pharmacological effects. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | The potential reduction in antiretroviral efficacy should be considered before initiating treatment with orlistat. Patients who take antiretroviral medications should be advised to consult their physician before using the non-prescription brand of orlistat. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MHRA. Medicines and Healthcare Products Regulatory Agency "Orlistat: theoretical interaction with antiretroviral HIV medicines.". | ||||||||||||||||||